Breaking New Ground
AEON Biopharma is breaking new ground as the only company exclusively dedicated to the use of botulinum toxins for the treatment of debilitating medical conditions. Our therapeutic-only focus will allow AEON Biopharma to advance safe and effective treatment options to patients, while delivering differentiated economics to payers and physicians.
Innovative Biotherapy You Can Trust
Botulinum toxin use goes far beyond aesthetic applications, holding the power to provide relief to patients suffering from the pain and functional impairment associated with numerous medical conditions. We believe our botulinum toxin could have therapeutic applications in a broad range of debilitating medical conditions and could enhance treatment and improve the quality of life for these patients.
Established Botulinum Toxin
AEON Biopharma is focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions. We are dedicated to innovation in the rapidly expanding therapeutic botulinum toxin market. AEON Biopharma continues to evaluate additional therapeutic indications for development based on a comprehensive product assessment process designed to identify those indications where we believe ABP-450 can attain clinical, regulatory and commercial success.
